XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange
XORTX Therapeutics (XRTX.V, XRTX) on Monday provided a corporate update and announced the appointment of Mika Grasso as co-chief executive officer, responsible for finance and public markets.This comes after the company had said after markets closed on Friday that it has elected to voluntarily delist its common shares from the TSX Venture Exchange. It will provide additional information on timing for the completion of the delisting of its common shares in a separate press release."This decision was taken following a comprehensive evaluation, the company determined that maintaining a dual listing on the TSXV does not justify the associated costs and administrative requirements and presents challenges due to the different regulatory environments," the company said. "It is envisioned that the voluntary delisting will eliminate duplicative exchange fees, reduce legal and accounting expenses, optimize company financing initiatives and minimize regulatory complexity, and enable greater management focus on the advancement of the XRx-026 program for the treatment of gout for long-term shareholder value creation."